Clinical trials: Diffuse-large B-cell Lymphoma (DLBCL)
Large B-Cell Lymphoma (LBCL)
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.
- Trial name
- Go-Pro-DLBCL (NCT07269639)
- Testing
- Golcadomide + Poseltinib + Rituximab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown…
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas, Indolent B Cell Lymphoma
- Trial name
- REVERSE_2021 (NCT06822829)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Diffuse Large B Cell Lymphoma (DLBCL)
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
- Trial name
- GRAIL (NCT06050694)
- Testing
- glofitamab
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Diffuse Large B-Cell Lymphoma
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
[Phase I part] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05658562
- Testing
- MT-2111
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Non-Hodgkins Lymphoma
A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
There has been considerable international /national interest in the GEM-P regimen for treatment of patients with relapsed/refractory lymphoma. Currently, there is no accepted standard therapy for these patients.
- Trial name
- NCT00301301
- Testing
- Gemcitabine, Cisplatinum, Rituximab
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diffuse Large B-cell Lymphoma
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
- Trial name
- NCT00968331
- Testing
- Lenalidomide plus Rituximab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Bologna
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
This is a single-arm, open-label phase 2 study of iR2 in the treatment of unfit and elderly patients with untreated diffuse large B-cell lymphoma。
- Trial name
- NCT03949062
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Diffuse Large B-Cell Lymphoma
Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or resistant Diffuse Large B Cell Lymphoma (DLBCL)…
- Trial name
- COBALT (NCT02431988)
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Non Hodgkin's Lymphoma
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem…
- Trial name
- NCT01063439
- Testing
- Busulfan, Etoposide, Cytarabine, Melphalan
- Where
- 5 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- Inje University
Lymphoma
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL.
- Trial name
- NCT01889069
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 39 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory…
- Trial name
- NCT01453205
- Testing
- MEDI-551 2 mg/kg, Rituximab, ICE
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 187 people
- Sponsor
- MedImmune LLC
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
- Trial name
- LOTIS 5 (NCT04384484)
- Testing
- Loncastuximab Tesirine, Rituximab, Gemcitabine
- Where
- 144 sites in United States, Argentina and 19 more
- Volunteers
- 440 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma (DLBCL)
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten…
- Trial name
- NCT07887750
- Testing
- REGN9220, Odronextamab
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, Large B-Cell, Diffuse
Thalidomide Maintenance Treatment in DLBCL
This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).
- Trial name
- NCT03016000
- Testing
- Thalidomide, Observation
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL)
REal World Data in LYmphoma and Survival in Adults
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.
- Conditions
- Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL)
- Trial name
- REALYSA (NCT03869619)
- Testing
- Real-life epidemiological platform of lymphoma in France
- Where
- 37 sites in France
- Volunteers
- 6,000 people
- Sponsor
- Hospices Civils de Lyon
Diffuse Large B-cell Lymphoma
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase II, single institution, single-arm, open-label study of oral dasatinib monotherapy administered to subjects with relapsed or refractory aggressive DLBCL.
- Trial name
- NCT00918463
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University